Reperfusion options in ST-elevation myocardial infarction patients with expected delays.

Current Cardiology Reports
David M Larson, Timothy D Henry

Abstract

Primary percutaneous coronary intervention (PPCI) is the optimal reperfusion strategy for ST-elevation myocardial infarction (STEMI) patients when performed in a timely manner by experienced providers. Unfortunately, only 25% of US hospitals have percutaneous coronary intervention (PCI) capability. Transfer for PPCI has also been shown to improve outcomes if transfer times are short and PCI can be performed within 90 minutes. However, many STEMI patients cannot be transferred in a timely fashion because of long distances, adverse weather, or process-of-care delays. Recent data support strategies that combine fibrinolysis with transfer for PCI under these circumstances. The critical issue that is still debated is the timing of PCI (immediate vs delayed vs rescue). The significance of time to reperfusion to mortality is important but less critical for PCI than for fibrinolysis, but time still matters. To optimize time to reperfusion for STEMI patients, all hospitals need to have predetermined protocols in place based on hospital characteristics and proximity to a catheterization laboratory.

References

Jun 1, 1996·Journal of the American College of Cardiology·L K NewbyF Van de Werf
Dec 8, 2000·Italian heart journal. Supplement : official journal of the Italian Federation of Cardiology·G Bernardi
May 29, 2002·The American Journal of Cardiology·David AntoniucciGiovanni Maria Santoro
Aug 23, 2003·Journal of the American College of Cardiology·Bruno SchellerUNKNOWN SIAM III Study Group
Sep 19, 2003·Journal of the American College of Cardiology·Giuseppe De LucaUNKNOWN ZWOLLE Myocardial Infarction Study Group
Oct 1, 2003·The American Journal of Cardiology·Brahmajee K Nallamothu, Eric R Bates
Feb 26, 2004·JAMA : the Journal of the American Medical Association·Adnan KastratiUNKNOWN Bavarian Reperfusion Alternatives Evaluation (BRAVE) Study Investigators
Oct 28, 2004·JAMA : the Journal of the American Medical Association·David E WennbergDavid J Malenka
Jun 16, 2005·JAMA : the Journal of the American Medical Association·Albert SchömigUNKNOWN Beyond 12 hours Reperfusion AlternatiVe Evaluation (BRAVE-2) Trial Investigators
Aug 2, 2005·Journal of the American College of Cardiology·Michel R Le MayLyall A Higginson
Dec 31, 2005·The New England Journal of Medicine·Anthony H GershlickUNKNOWN REACT Trial Investigators
Feb 21, 2006·Lancet·UNKNOWN Assessment of the Safety and Efficacy of a New Treatment Strategy with Percutaneous Coronary Intervention (ASSENT-4 PCI) inv
Jun 6, 2006·Journal of the American College of Cardiology·Robert L McNamaraUNKNOWN NRMI Investigators
Jun 13, 2006·The American Journal of Cardiology·Taral N PatelStephen G Ellis
Oct 13, 2006·JAMA : the Journal of the American Medical Association·Ulf StenestrandUNKNOWN RIKS-HIA Registry
Jan 25, 2007·European Heart Journal·Francisco Fernández-AvilésUNKNOWN GRACIA-2 (Groupo de Análisis de Cardiopatía Isquémica Aguda) Investigators
Jan 18, 2008·The New England Journal of Medicine·Michel R Le MayMarino Labinaz
May 24, 2008·The New England Journal of Medicine·Stephen G EllisUNKNOWN FINESSE Investigators

❮ Previous
Next ❯

Citations


❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.